Endogenex Raises $50 Million to Advance Type 2 Diabetes Treatment
Endogenex, a Minneapolis-based medical technology company, has successfully closed a $50 million Series C extension round. The company, which collaborates with the Mayo Clinic to develop innovative treatment solutions for Type 2 Diabetes, aims to address the condition for patients, healthcare providers, and systems worldwide. This funding round was led by Arboretum Ventures.
Funding Details and Leadership
The Series C extension, finalized on March 25, 2026, was spearheaded by lead investor Arboretum Ventures. The funds will support Endogenex's ongoing efforts to bring its novel treatment method to market. Stacey Pugh, the company's Chief Executive Officer, highlighted the importance of the funding: "This financing puts us in a strong position to complete our pivotal study and take the ReCET System through FDA approval."
Innovative Treatment Approach
Endogenex is developing a minimally invasive outpatient procedure that utilizes non-thermal pulsed electric fields to treat inflamed tissue in the duodenum, the first section of the small intestine. The procedure is designed to promote healthy cell regeneration and improve the gut's ability to communicate with other organs that regulate blood sugar, appetite, digestion, and metabolism. This innovative approach targets the duodenum's inflammation, which is increasingly recognized as a factor that can exacerbate Type 2 Diabetes.
Strategic Use of Funds
The newly acquired funds will primarily be used to complete the pivotal ReCET Clinical Study, a crucial step in advancing Endogenex's treatment to the next phase of regulatory approval. The company is focused on securing FDA approval for its ReCET System, which it believes will significantly impact the management of Type 2 Diabetes.
Looking Ahead
With the support of Arboretum Ventures and the successful closing of this funding round, Endogenex is well-positioned to continue its clinical studies and regulatory processes. The company's goal is to offer a new, effective treatment option for millions of individuals affected by Type 2 Diabetes, potentially transforming current management strategies for this widespread condition.